Is Jazz Pharmaceuticals (JAZZ) Offering Value After Recent Pullback And 32.7% One Year Gain

• If you are wondering whether Jazz Pharmaceuticals is offering good value at around US$161.13 per share, this article walks through what that price could mean for you as an investor.

• The stock is down 6.9% over the last week and 3.8% over the last month, yet it is up 32.7% over the past year. This mix of short-term weakness and longer-term strength may change how you think about its risk and return profile.

• Recent coverage has focused on Jazz Pharmaceuticals as a specialty pharma name in focus, with attention on how its current product portfolio and pipeline position the business within the broader pharmaceuticals and biotech sector. That context helps frame why the shares have pulled back in the short term while still sitting on a stronger 1 year return of 32.7%.

• On our valuation checks, Jazz Pharmaceuticals currently scores 6 out of 6. Next we will look at what that means across different valuation methods, before finishing with a simple way to keep all this valuation work in perspective.

Jazz Pharmaceuticals delivered 32.7% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

A Discounted Cash Flow model takes the cash a business is expected to generate in the future, then discounts those cash flows back to today to estimate what the whole company could be worth right now.

For Jazz Pharmaceuticals, the model uses a 2 Stage Free Cash Flow to Equity approach built on cash flow projections. The latest twelve month free cash flow is about $1.18b. Analyst forecasts are used for the next few years, then Simply Wall St extrapolates further out, with projected free cash flow of $2.10b in 2030. Each of these future figures is discounted back to today and summed to arrive at an estimated value for the equity.

On this basis, the DCF model suggests an intrinsic value of about $772.86 per share, compared with the current share price of roughly $161.13. That implies an intrinsic discount of 79.2%, which indicates that the shares are trading well below the DCF estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Jazz Pharmaceuticals is undervalued by 79.2%. Track this in your watchlist or portfolio, or discover 882 more undervalued stocks based on cash flows.

JAZZ Discounted Cash Flow as at Jan 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Jazz Pharmaceuticals.

For a profitable pharmaceutical company with meaningful revenue, the P/S ratio can be a useful way to think about what you are paying for each dollar of sales, especially when earnings are affected by items like amortisation or R&D.

Story Continues

In simple terms, higher expected growth and lower perceived risk usually support a higher “normal” or “fair” P/S multiple, while slower growth or higher risk tend to justify a lower one. That context matters when you compare Jazz Pharmaceuticals with its sector.

Jazz Pharmaceuticals currently trades on a P/S of 2.35x. This is below both the Pharmaceuticals industry average P/S of 4.30x and the peer group average of 5.88x. Simply Wall St also calculates a proprietary “Fair Ratio” for Jazz of 7.08x, which reflects factors such as its earnings growth profile, profit margins, industry, market cap and company specific risks.

The Fair Ratio aims to be more tailored than a simple peer or industry comparison because it blends those company specific drivers into one benchmark, rather than assuming that all pharma names deserve the same multiple.

Compared with the current 2.35x P/S, the Fair Ratio of 7.08x suggests that Jazz Pharmaceuticals shares look undervalued on this metric.

Result: UNDERVALUED

NasdaqGS:JAZZ P/S Ratio as at Jan 2026

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1444 companies where insiders are betting big on explosive growth.

Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach your own story about Jazz Pharmaceuticals, including your assumptions for future revenue, earnings, margins and fair value. You can then link that story to a financial forecast and compare your fair value with the current price in a simple, visual way that updates when new earnings or news arrive. For example, one investor might build a very optimistic Jazz Narrative around oncology leadership with a fair value close to US$230. Another might focus more on patent expiries and competition with a fair value nearer US$147. You can see both of these and many others on the Jazz Pharmaceuticals Community page to help you decide what makes the most sense to you.

Do you think there’s more to the story for Jazz Pharmaceuticals? Head over to our Community to see what others are saying!

NasdaqGS:JAZZ 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include JAZZ.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

No Byline Policy

Editorial Guidelines

Corrections Policy

Source